Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma

14 november 2026 bijgewerkt door: zhanglin, Beijing Tsinghua Chang Gung Hospital

Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study

This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.

Studietype

Observationeel

Inschrijving (Geschat)

200

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 102218
        • Beijing Tsinghua Changgung Hospital
        • Contact:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400038
        • Southwest Hospital, Army Medical University
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 350025
        • Mengchao Hepatobiliary Hospital of Fujian Medical University
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, China, 510630
        • The First Affiliated Hospital of Jinan University
        • Contact:
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • The First Hospital of China Medical University
        • Contact:
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.

Beschrijving

Inclusion Criteria:

  1. Initially unresectable primary liver cancer.
  2. Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
  3. Postoperative histopathological examination confirmed HCC.

Exclusion Criteria:

  1. Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
  2. Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
  3. Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
  4. Failure to achieve R0 resection.
  5. Incomplete clinical data.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: OTHER

Cohorten en interventies

Groep / Cohort
90Y-SIRT-Based Conversion Therapy Group

Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

TACE-Based Conversion Therapy Group

Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Postoperative recurrence-free survival (RFS)
Tijdsspanne: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Postoperative overall survival (OS)
Tijdsspanne: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
Pathological complete response (pCR) rate
Tijdsspanne: Immediately after curative-intent hepatectomy.

pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments.

Immediately after curative-intent hepatectomy.
Major pathological response (MPR) rate
Tijdsspanne: Immediately after curative-intent hepatectomy.

MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments.

Immediately after curative-intent hepatectomy.
Microvascular invasion (MVI) positivity rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
Immediately after curative-intent hepatectomy.
Satellite nodule positivity rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
Immediately after curative-intent hepatectomy.
Postoperative complication rate
Tijdsspanne: Perioperatively, from curative-intent hepatectomy through hospital discharge.

The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria.

Perioperatively, from curative-intent hepatectomy through hospital discharge.

Andere uitkomstmaten

Uitkomstmaat
Tijdsspanne
Percentage change in tumor markers
Tijdsspanne: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
Percentage change in maximum tumor diameter
Tijdsspanne: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2031

Studie voltooiing (Geschat)

1 december 2036

Studieregistratiedata

Eerst ingediend

10 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren